BCIQ Profiles

Company Profile Report
0630 adu Duke
BioCentury & Getty Images

Product Development

FDA scheduled Alzheimer’s drug coverage meeting with payers before aducanumab approval

Jul 1, 2021 | 1:42 AM GMT

FDA has commissioned Duke-Margolis Center to organize a private roundtable meeting in July with payers and other stakeholders to discuss challenges associated with covering and developing evidence for Alzheimer’s therapies such as aducanumab from Biogen and Eisai.

Payers were invited to the roundtable in the spring, before Aduhelm aducanumab’s approval. BioCentury spoke with three invited participants who did not want to be identified because the meeting is private. One

Read the full 937 word article

How to gain access

Continue reading with a
two-week free trial.